KRAS G12D Mutations
2
Pipeline Programs
2
Companies
2
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2024
2025
2026
2027
2028
Ranok TherapeuticsRNK08954
GenFleet TherapeuticsGFH375
Clinical Trials (2)
Total enrollment: 467 patients across 2 trials
To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.
Start: Oct 2025Est. completion: Nov 202660 patients
Phase 2Recruiting
A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
Start: Jul 2024Est. completion: Dec 2028407 patients
Phase 1/2Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 467 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.